[
    {
        "molecule_name": "imidazo [1,2-a ] pyridine derivatives",
        "protein_target_name": "HDAC6",
        "binding_metric": "ic50",
        "value": "22.96",
        "unit": "μm",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. The invention has the following positive and beneficial effects: the imidazo [1,2-a ] pyridine derivatives of the present invention have the strongest antiproliferative activity (ic50=22.96 μm) on the human neuroblastoma SH-SY5Y cell line, are slightly superior to the clinically approved HDAC inhibitor SAHA (ic50=25.16 μm), represent a new class of central nervous system penetrating agent HDAC6 inhibitors, and show therapeutic potential for brain cancer and central nervous system diseases."
    },
    {
        "molecule_name": "SAHA",
        "protein_target_name": "HDAC",
        "binding_metric": "ic50",
        "value": "25.16",
        "unit": "μm",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n1. The invention has the following positive and beneficial effects: the imidazo [1,2-a ] pyridine derivatives of the present invention have the strongest antiproliferative activity (ic50=22.96 μm) on the human neuroblastoma SH-SY5Y cell line, are slightly superior to the clinically approved HDAC inhibitor SAHA (ic50=25.16 μm), represent a new class of central nervous system penetrating agent HDAC6 inhibitors, and show therapeutic potential for brain cancer and central nervous system diseases."
    }
]